PortfoliosLab logoPortfoliosLab logo
Frequency Therapeutics Inc (KRRO)
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Company Info

IPO Date
Nov 6, 2023

Highlights

Market Cap
$106.36M
Enterprise Value
$130.69M
EPS (TTM)
-$12.48
Total Revenue (TTM)
$6.39M
Gross Profit (TTM)
$5.10M
EBITDA (TTM)
-$117.05M
Year Range
$5.20 - $55.89
Target Price
$19.43
ROA (TTM)
-103.31%
ROE (TTM)
-227.96%

Share Price Chart


Loading graphics...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Frequency Therapeutics Inc

Often compared with KRRO:
KRRO vs. PRAX

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Frequency Therapeutics Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


Loading graphics...

S&P 500 Index

Returns By Period

Frequency Therapeutics Inc (KRRO) has returned 41.32% so far this year and -34.98% over the past 12 months.


Frequency Therapeutics Inc

1D
10.12%
1M
-6.68%
YTD
41.32%
6M
-76.36%
1Y
-34.98%
3Y*
5Y*
10Y*

Benchmark (S&P 500 Index)

1D
2.91%
1M
-5.09%
YTD
-4.63%
6M
-2.39%
1Y
16.33%
3Y*
16.69%
5Y*
10.18%
10Y*
12.16%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Monthly Returns

Based on dividend-adjusted daily data since Nov 6, 2023, KRRO's average daily return is +0.36%, while the average monthly return is +10.97%. At this rate, your investment would double in approximately 0.6 years.

Historically, 48% of months were positive and 52% were negative. The best month was Nov 2023 with a return of +170.7%, while the worst month was Nov 2025 at -86.1%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 5 months.

On a daily basis, KRRO closed higher 49% of trading days. The best single day was Oct 16, 2024 with a return of +93.7%, while the worst single day was Nov 13, 2025 at -79.3%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202666.42%-9.00%-6.68%41.32%
2025-10.38%-26.52%-30.55%1.95%-35.66%9.37%19.78%54.28%107.50%-14.58%-86.07%40.53%-78.96%
20246.01%-4.94%86.34%-36.90%-9.67%-33.98%37.47%2.49%-29.97%72.05%-9.46%-26.87%-20.57%
2023170.74%14.36%209.63%

Benchmark Metrics

Frequency Therapeutics Inc has an annualized alpha of 75.11%, beta of 1.87, and R² of 0.04 versus S&P 500 Index. Calculated based on daily prices since November 07, 2023.

  • This stock participated in 239.71% of S&P 500 Index downside but only 58.94% of its upside — more exposed to losses than it benefited from rallies.
  • R² of 0.04 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
75.11%
Beta
1.87
0.04
Upside Capture
58.94%
Downside Capture
239.71%

Return for Risk

Risk / Return Rank

KRRO ranks 39 for risk / return — below 39% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.


KRRO Risk / Return Rank: 3939
Overall Rank
KRRO Sharpe Ratio Rank: 2828
Sharpe Ratio Rank
KRRO Sortino Ratio Rank: 5151
Sortino Ratio Rank
KRRO Omega Ratio Rank: 5555
Omega Ratio Rank
KRRO Calmar Ratio Rank: 2828
Calmar Ratio Rank
KRRO Martin Ratio Rank: 3030
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for Frequency Therapeutics Inc (KRRO) and compare them to a chosen benchmark (S&P 500 Index).


KRROBenchmarkDifference

Sharpe ratio

Return per unit of total volatility

-0.27

0.90

-1.17

Sortino ratio

Return per unit of downside risk

0.86

1.39

-0.53

Omega ratio

Gain probability vs. loss probability

1.14

1.21

-0.07

Calmar ratio

Return relative to maximum drawdown

-0.39

1.40

-1.79

Martin ratio

Return relative to average drawdown

-0.65

6.61

-7.26

Explore KRRO risk-adjusted metrics in detail

Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.

Dividends

Dividend History


Frequency Therapeutics Inc doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading graphics...

Worst Drawdowns

The table below displays the maximum drawdowns of the Frequency Therapeutics Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Frequency Therapeutics Inc was 94.13%, occurring on Dec 2, 2025. The portfolio has not yet recovered.

The current Frequency Therapeutics Inc drawdown is 87.42%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-94.13%Apr 1, 2024421Dec 2, 2025
-32.22%Feb 6, 202416Feb 28, 202418Mar 25, 202434
-29.28%Dec 5, 202330Jan 18, 202412Feb 5, 202442
-26.17%Nov 14, 20239Nov 27, 20235Dec 4, 202314
-0.68%Nov 9, 20231Nov 9, 20231Nov 10, 20232

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading graphics...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Frequency Therapeutics Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Frequency Therapeutics Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for KRRO relative to other companies in the Biotechnology industry. Currently, KRRO has a P/S ratio of 16.6. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for KRRO in comparison with other companies in the Biotechnology industry. Currently, KRRO has a P/B value of 2.1. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items